Sugi Predict

Sugi Predict / Compounds / SCHEMBL679511

SCHEMBL679511

SCHEMBL679511

Cc1ccc(C(=O)Nc2ccc(Oc3cc4cn[nH]c4cc3N3CCO[C@H](C)C3)c(F)c2)c(=O)n1-c1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 14/20 0.55
▸ MET P08581 14/20 0.52
▸ MERTK Q12866 5/20 0.52
▸ KDR P35968 4/20 0.52
▸ PLK4 O00444 1/20 0.52
▸ NTRK1 P04629 1/20 0.52
▸ RET P07949 1/20 0.52
▸ FLT3 P36888 1/20 0.52
▸ MST1R Q04912 1/20 0.52
▸ DDR1 Q08345 1/20 0.52
▸ CAMK4 Q16566 1/20 0.52
▸ DDR2 Q16832 1/20 0.52
▸ MKNK1 Q9BUB5 1/20 0.52
▸ MKNK2 Q9HBH9 1/20 0.52
▸ TYRO3 Q06418 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679512 1.00 AXL (0.55) AXLMETMERTKKDRPLK4
SCHEMBL680780 0.91 AXL (0.64) AXLMETMERTKKDRPLK4
SCHEMBL681026 0.89 AXL (0.53) AXLMETMERTKKDRFLT3
SCHEMBL681013 0.89 AXL (0.53) AXLMETMERTKKDRFLT3
SCHEMBL12190724 0.85 MET (0.64) AXLMETMERTKKDRPLK4
SCHEMBL679482 0.84 AXL (0.58) AXLMETMERTKKDRPLK4
SCHEMBL681014 0.83 KDR (0.37) AXLMETMERTKKDRPLK4
SCHEMBL680235 0.82 AXL (0.61) AXLMETMERTKKDRPLK4
SCHEMBL681095 0.82 AXL (0.61) AXLMETMERTKKDRPLK4
SCHEMBL680702 0.82 AXL (0.57) AXLMETMERTKKDRPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 — — US disclosed
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 — — US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 — — EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 — — US disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 — — US disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 — — US disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 — — US disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 — — US disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC AXL 113/4885MET 1/4885MERTK 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.